TABLE 3

Complete responder versus noncomplete responder characteristics at baseline

nComplete responders (n=289)nNoncomplete responders (n=213)p-value
Age, years28958±1221356±130.12
Female289129 (45)213115 (54)0.038
BMI, kg·m−228728±521128±60.28
Duration of disease, years17920±1712924±190.04
Duration of disease >10 years179107 (60)12987 (67)0.169
Age at onset, years17938±2012932±210.02
Onset during childhood ≤18 years18646 (25)13547 (35)0.131
Late onset ≥40 years18690 (48)13554 (40)0.131
Exacerbations in year before biologic, n2192.80±2.611723.43±3.610.049
Budesonide-equivalent dose, µg1951600 (1200–1600)1551600 (1600–2000)0.23
mOCS28952 (18)213134 (63)<0.0001
 Median dose, mg467.5 (5–10)9110 (7.5–15)0.03
Biologic2892130.125
 Mepolizumab207 (72)148 (69)
 Reslizumab10 (3)16 (8)
 Benralizumab72 (25)49 (23)
Switchers28966 (23)21363 (29)0.08
FEV1, L2482.26±0.851882.18±0.830.31
FEV1, % pred24670±2118668±210.41
FEV1/FVC2370.64±0.131840.65±0.130.70
ACQ score1682.32±1.321442.67±1.240.01
Blood eosinophils, ×109 L−12340.40 (0.18–0.65)1810.23 (0.1–0.54)0.0002
Blood eosinophils ≥0.3×109 L−1234146 (62)18181 (45)0.0003
IgE, IU·mL−1146141 (66–399)11270 (54–83)0.09
IgE ≥150 IU·mL−114671 (49)11248 (43)0.35
FENO, ppb20132 (18–64)15132 (14–63)0.65
Smoking status2812050.62
 Never-smoker151 (54)101 (49)
 Ex-smoker125 (44)100 (49)
 Current smoker5 (2)4 (2)
 Pack-years15.9±1317.7±14.40.33
Allergic rhinitis277132 (48)20382 (41)0.11
Atopic dermatitis27437 (14)20226 (13)0.84
Chronic rhinosinusitis273166 (61)201109 (54)0.15
Nasal polyps276122 (44)20286 (43)0.72
Aspirin sensitivity27427 (10)20112 (6)0.13
Bronchiectasis27653 (19)20246 (23)0.34
Vocal cord dysfunction2725 (2)1995 (3)0.61
ABPA2759 (3)2005 (3)0.62
EGPA27311 (4)2009 (5)0.80
Dysfunctional breathing27317 (6)20110 (5)0.56
COPD27061 (23)20055 (28)0.22
GORD27283 (31)20263 (31)0.87
Cardiovascular disease27482 (30)20167 (33)0.42
Diabetes27525 (9)20230 (15)0.05
OSA27326 (10)20229 (14)0.10

Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; mOCS: maintenance oral corticosteroids; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; FENO: exhaled nitric oxide fraction; ABPA: allergic bronchopulmonary aspergillosis; EGPA: eosinophilic granulomatosis with polyangiitis; COPD: chronic obstructive pulmonary disease; GORD: gastro-oesophageal reflux disease; OSA: obstructive sleep apnoea.